Functional goal achievement in post-stroke spasticity patients: The Botox® Economic Spasticity Trial (BEST)

Journal of Rehabilitation Medicine

Volumn 46, Issue 6, 2014, Pages 504-513

  Ward, Anthony B ^a   Wissel, Jörg ^b   Borg, Jörgen ^c   Ertzgaard, Per ^d   Herrmann, Christoph ^e   Kulkarni, Jai ^f   Lindgren, Kristina ^g   Reuter, Iris ^h   Sakel, Mohamed ⁱ   Säterö, Patrik ^j   Sharma, Satyendra ^k   Wein, Theodore ^l   Wright, Nicola ^m   Fulford Smith, Antony ^m  

^a HAYWOOD HOSPITAL   (United Kingdom)

^b Vivantes Klinikum Spandau   (Germany)

^c DANDERYD HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

^e Clinics for Neurological Rehabilitation and Early Rehabilitation Asklepios Clinics Schildautal   (Germany)

^f MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^g CENTRAL HOSPITAL   (Sweden)

^h JUSTUS LIEBIG UNIVERSITY   (Germany)

ⁱ KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^j SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^k SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^l MONTREAL GENERAL HOSPITAL   (Canada)

^m ALLERGAN PLC   (United States)

more..

Author keywords

Botulinum neurotoxin A; Functional change; Goal attainment scaling; OnabotulinumtoxinA; Post stroke spasticity; Rehabilitation

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT; PLACEBO;

ACHIEVEMENT; ADULT; AGED; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INJECTION; MALE; MIDDLE AGED; MOTIVATION; MULTICENTER STUDY; MUSCLE SPASTICITY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STROKE; VERY ELDERLY; YOUNG ADULT;

ACHIEVEMENT; ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; FEMALE; GOALS; HUMANS; INJECTIONS; MALE; MIDDLE AGED; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; PLACEBOS; PROSPECTIVE STUDIES; STROKE; YOUNG ADULT;

EID: 84903980766     PISSN: 16501977     EISSN: None     Source Type: Journal    
DOI: 10.2340/16501977-1817     Document Type: Article

References (40)

1. Ashford S, Turner-Stokes L. Management of shoulder and proximal upper limb spasticity using botulinum toxin and concurrent therapy interventions: A preliminary analysis of goals and outcomes. Disabil Rehabil 2009; 31: 220-226.
2. Bakheit AMO, Fedorova NV, Skoromets AA, Timerbaeva SL, Bhakta BB, Coxon L. The beneficial antispasticity benefit of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 2004; 75: 1558-1561.
3. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002; 347: 395-400.
4. Elovic E, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, Turkel C. Repeated treatments with botulinum toxin type A produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil 2008; 89: 799-806.
5. Turner-Stokes L, Baguley IJ, De Graaff S, Katrak P, Davies L, McCrory P, Hughes A. Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: A secondary analysis from a double-blind placebo-controlled randomized clinical trial. J Rehabil Med 2010; 42: 81-89.
6. Kanovsky P, Slawek J, Denes Z, Platz T, Comes G, Grafe S, Pulte I. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med 2011; 43: 486-492.
7. Morris SL, Dodd KJ, Morris ME. Outcomes of progressive resistance strength training following stroke: a systematic review. Clin Rehabil 2004; 18: 27-39.
8. Langhorne P, Coupar F, Pollock A. Motor recovery after stroke: a systematic review. Lancet Neurol 2009; 8: 741-754.
9. Wevers L, van de Port I, Vermue M, Mead G, Kwakkel G. Effects of task-oriented circuit class training on walking competency after stroke: A systematic review. Stroke 2009; 40: 2450-2459.
10. Bakheit AMO, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, et al. A randomized, double-blind, placebo-controlled, doseranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000; 31: 2402-2406.
11. McCrory P, Turner-Stokes L, Baguley IJ, De Graaff S, Katrak P, Sandanam J, et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebocontrolled study of the effects on quality of life and other personcentred outcomes. J Rehabil Med 2009; 41: 536-544.
12. Meythaler JM, Vogtle L, Brunner RC. A preliminary assessment of the benefits of the addition of botulinum toxin A to a conventional therapy program on the function of people with longstanding stroke. Arch Phys Med Rehabil 2009; 90: 1453-1461.
13. Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N, et al. BoTULS: a multicentre randomized controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technol Assess 2010; 14: 1-113.
14. Sun SF, Hsu CW, Sun HP, Hwang CW, Yang CL, Wang JL. Combined botulinum toxin type A with modified constraint-induce movement therapy for chronic stroke patients with upper extremity spasticity: a randomized controlled study. Neurorehabil Neural Repair 2010; 24: 34-41.
15. Shaw LC, Price CI, van Wijck FM, Shackley P, Steen N, Barnes MP, et al. Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial: effect on impairment, activity limitation, and pain. Stroke 2011; 42: 1371-1379.
16. Wolf SL, Milton SB, Reiss A, Easley KA, Shenvi NV, Clark PC. Further assessment to determine the additive effect of botulinum toxin type A on an upper extremity exercise program to enhance function among individuals with chronic stroke but extensor capability. Arch Phys Med Rehabil 2012; 93: 578-587.
17. Borg J, Ward AB, Wissel J, Kulkarni J, Sakel M, Ertzgaard P, et al. Rationale and design of a multicentre, double-blind, prospective, randomized, European and Canadian study: evaluating patient outcomes and costs of managing adults with post-stroke focal spasticity. J Rehabil Med 2011; 43: 15-22.
18. Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996; 61: 30-35.
19. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum type A on disability and carer burden due to arm spasticity after stroke: a randomized double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000; 69: 217-221.
20. Platz T, Vuadens P, Eickhof C, Arnold P, Van Kaick S, Heise K. REPAS - a summary rating scale for resistance to passive movement: item selection, reliability and validity. Disabil Rehabil 2008; 30: 44-53.
21. Lin PY, Yang YR, Cheng SJ, Wang RY. The relation between ankle impairments and gait velocity and symmetry in people with stroke. Arch Phys Med Rehabil 2006; 87: 562-568.
22. Ng SS, Hui-Chan CW. Contribution of ankle dorsiflexor strength to walking endurance in people with spastic hemiplegia after stroke. Arch Phys Med Rehabil 2012; 93: 1046-1051.
23. Bovend'Eerdt TJH, Botell RE, Wade DT. Writing SMART rehabilitation goals and achieving goal attainment scaling: a practical guide. Clin Rehabil 2009; 23: 352-361.
24. White MA, Verhoef MJ. Toward a patient-centered approach: icorporating principles of participatory action research into clinical studies. Integr Cancer Ther 2005; 4: 21-24.
25. Ertzgaard P, Ward AB, Wissel J, Borg J. Practical considerations for goal attainment scaling during rehabilitation following acquired brain injury. J Rehabil Med 2011; 43: 8-14.
26. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540-542.
27. Hesse S, Mach H, Fröhlich S, Behrend S, Werner C, Melzer I. An early botulinum toxin A treatment in subacute stroke patients may prevent a disabling finger flexor stiffness six months later: a randomized controlled trial. Clin Rehabil 2012; 26: 237-245.
28. Hiraoka K, Abe K. Cortical and spinal control of ankle joint muscles before and during gait initiation. Somatosens Mot Res 2007; 24: 127-133.
29. Iglesias C, Nielsen JB, Marchand-Pauvert V. Corticospinal inhibition of transmission in propriospinal-like neurones during human walking. Eur J Neurosci 2008; 28: 1351-1361.
30. Kuhtz-Buschbeck JP, Ehrsson HH, Forssberg H. Human brain activity in the control of fine static precision grip forces: an fMRI study. Eur J Neurosci 2001; 14: 382-390.
31. Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol 2010; 257: 1330-1337.
32. Dunne JW, Gracies JM, Hayes M, Zeman B, Singer BJ, Multicentre Study Group. A prospective, multicentre, randomized, double-blind, placeco-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke. Clin Rehabil 2012; 26: 787-797.
33. Evans JJ. Goal setting during rehabilitation early and late after acquired brain injury. Curr Opin Neurol 2012; 25: 651-655.
34. Rosales RL, Dressler D. On muscle spindles, dystonia, and botulinum toxin. Eur J Neurol 2010; 17 Suppl 1: 71-80.
35. Ashford S, Turner-Stokes L. Goal attainment for spasticity management using botulinum toxin. Physiother Res Int 2006; 11: 24-34.
36. Bouwens SF, van Heugten CM, Verhey FR. The practical use of goal attainment scaling for people with acquired brain injury who receive cognitive rehabilitation. Clin Rehabil 2009; 23: 310-320.
37. Sommerfeld DK, Eek EU-B, Svensson A-K, Widen Holmqvist L, von Arbin MH. Spasticity after stroke: Its occurrence and association with motor impairments and activity limitations. Stroke 2004; 35: 134-140.
38. Lundstrom E, Smits A, Terent A, Borg J. Time-course and determinants of spasticity during the first six months following first-ever stroke. J Rehabil Med 2010; 42: 296-301.
39. Wissel J, Schelosky LD, Scott J, Christe W, Faiss JH, Mueller J. Early development of spasticity following stroke: a prospective, observational trial. J Neurol 2010; 257: 1067-1072.
40. Intercollegiate Stroke Working Party. National clinical guideline for stroke. 3rd ed. London: Royal College of Physicians, 2008.